ACRS (STOCKS)
Aclaris Therapeutics, Inc.
$4.360000
+0.040000 (+0.93%)
Prev close: $4.320000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Neal S. Walker
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $609.63M
- Employees
- 64
- P/E (TTM)
- -7.71
- P/B (TTM)
- 4.20
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $8.37M |
| Benefits Costs and Expenses | $78.03M |
| Cost Of Revenue | $1.98M |
| Costs And Expenses | $88.85M |
| Gross Profit | $6.39M |
| Nonoperating Income/Loss | $10.82M |
| Operating Expenses | $86.87M |
| Research and Development | $56.72M |
| Other Operating Expenses | $30.15M |
| Operating Income/Loss | -$80.48M |
| Income/Loss From Continuing Operations After Tax | -$69.66M |
| Income/Loss From Continuing Operations Before Tax | -$69.66M |
| Net Income/Loss | -$69.66M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$69.66M |
| Net Income/Loss Available To Common Stockholders, Basic | -$69.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.56 |
| Diluted Earnings Per Share | -$0.56 |
| Basic Average Shares | 374,044,037 |
| Diluted Average Shares | 374,044,037 |
| Assets | $198.72M |
| Current Assets | $110.23M |
| Cash | $190.80M |
| Noncurrent Assets | $88.49M |
| Fixed Assets | $750.00K |
| Other Non-current Assets | $87.74M |
| Liabilities | $55.07M |
| Current Liabilities | $27.37M |
| Accounts Payable | $14.73M |
| Wages | $2.04M |
| Other Current Liabilities | $10.60M |
| Noncurrent Liabilities | $27.70M |
| Equity | $143.65M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $143.65M |
| Liabilities And Equity | $198.72M |
| Net Cash Flow From Operating Activities | -$52.21M |
| Net Cash Flow From Operating Activities, Continuing | -$52.21M |
| Net Cash Flow From Investing Activities | -$1.69M |
| Net Cash Flow From Investing Activities, Continuing | -$1.69M |
| Net Cash Flow From Financing Activities | $52.19M |
| Net Cash Flow From Financing Activities, Continuing | $52.19M |
| Net Cash Flow | -$1.70M |
| Net Cash Flow, Continuing | -$1.70M |
| Comprehensive Income/Loss | -$70.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$70.07M |
| Other Comprehensive Income/Loss | -$412.00K |